European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Jul 11, 2025
Despite advances in the treatment of major depressive disorder (MDD) yet a substantial proportion of patients fail to achieve remission and instead develop treatment-resistant depression (TRD). Identifying robust clinical predictors of response is es...
Major Depressive Disorder is the most prominent global mental health issue impacting millions of individuals worldwide. Electroencephalogram signals capturing intricate brain dynamics have emerged as a promising modality for predicting depression. Th...
INTRODUCTION: The role of non-suicidal self-injury (NSSI) in the suicide process of people with major depressive disorder(MDD) remains controversial. Therefore, the purpose of this study was to investigate the role NSSI plays in suicide risk in peopl...
BACKGROUND: Major depressive disorder (MDD) is a prevalent and severe psychiatric condition for which objective diagnostic tools are lacking. Heart rate variability (HRV), an index of autonomic nervous system (ANS) function, has shown potential for d...
Suicide prevention is currently a global public health priority, since suicide has been a prevalent cause of death or potential loss of life. Multiple factors contribute to suicide risk, such as depression and a history of attempted suicide among oth...
PURPOSE: To identify biomarkers linking molecular mechanisms to macroscale brain changes in major depressive disorder (MDD) by integrating multimodal neuroimaging, transcriptomics, and machine learning.
BACKGROUND: Major depressive disorder (MDD) exhibits a multifactorial etiopathogenesis, yet current diagnosis still relies on clinician-rated symptom scales and phenomenological interviews, lacking validated biomarkers.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Jun 17, 2025
Nearly 60 % of individuals with bipolar disorder (BD) are initially classified as major depressive disorder (MDD) patients, resulting in inappropriate drug treatment. Identifying reliable biomarkers for the differential diagnosis between MDD and BD p...
BACKGROUND: Differentiating major depressive disorder (MDD) from bipolar disorder (BD) remains a significant clinical challenge, as both disorders exhibit overlapping symptoms but require distinct treatment approaches. Advances in voxel-based morphom...
BACKGROUND: Internet-delivered cognitive behavioural therapy (ICBT) is an effective and accessible treatment for mild to moderate depression and anxiety disorders. However, up to 50% of patients do not achieve sufficient symptom relief. Identifying p...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.